Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACI.0b013e32835e8b94 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A family-based behavioral group obesity randomized control feasibility trial across a clinical trials network: a focus on contact hours.
J Pediatr Psychol
January 2025
Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, United States.
Objective: This ancillary study's purpose is to describe the relationship between dose of treatment and body mass index (BMI) outcomes in a tele-behavioral health program delivered in the IDeA States Pediatric Clinical Trials Network to children and their families living in rural communities.
Methods: Participants randomized to the intervention were able to receive 26 contact hours (15 hr of group sessions and 11 hr of individual sessions) of material focused on nutrition, physical activity, and behavioral caregiver training delivered via interactive televideo. Dose of the intervention received by child/caregiver dyads (n = 52) from rural areas was measured as contact hours.
New PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy.
Mol Pharm
January 2025
Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents with limited effective preventive or therapeutic interventions. Although fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPARα) agonist, has demonstrated neuroprotective and analgesic properties, its clinical utility is hindered by low receptor affinity, poor subtype selectivity, and suboptimal bioavailability. A190, a highly selective and potent nonfibrate PPARα agonist, offers a promising alternative but is limited by poor aqueous solubility, resulting in reduced oral bioavailability and therapeutic efficacy.
View Article and Find Full Text PDFClinical, Laboratory, and Trichoscopic Features of Pediatric Androgenetic Alopecia.
Cutis
December 2024
Drs. Lu, Du, Zhao, and Fan and Lingbo Bi, Chaofan Wang, and Yunbu Ding are from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China. Yige Fan is from the Mayo Clinic, Rochester, Minnesota.
In this retrospective study, we analyzed the prevalence and impact of pediatric androgenetic alopecia (AGA). Over a 14-year period, 133 pediatric patients were evaluated, with manifestations of AGA appearing as early as age 10 years. The analysis included factors such as body mass index (BMI), family history of AGA, comorbidities, laboratory results, and patterns of hair loss.
View Article and Find Full Text PDFProgram Director Perspectives on DEI Initiatives in the Dermatology Residency Selection Process.
Cutis
December 2024
Ogechi Obed, Ivan Rodriguez, and Dr. Worswick are from the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles. Karen Lam is from the Department of Dermatology, David Geffen School of Medicine, University of California Los Angeles. Dr. Van Beek is from the Department of Dermatology, University of Iowa Health Care, Iowa City. Dr. Rosenblatt is from the Section of Dermatology, Departments of Medicine and Pediatrics, University of Chicago Pritzker School of Medicine, Illinois. Dr. Saavedra is from the Department of Dermatology, University of Virginia School of Medicine, Charlottesville.
The American Academy of Dermatology (AAD) has maintained a commitment to diversity, equity, and inclusion (DEI) initiatives; however, a recent strike down of affirmative action by the US Supreme Court has caused similar efforts to be called into question. This prompted our investigation into dermatology program director (PD) perceptions of DEI programming and its integration into resident selection. A cross-sectional survey of PDs at US dermatology residency programs was conducted from April 2024 to July 2024 (N=30).
View Article and Find Full Text PDFTreatment outcomes among children and adolescents with extensively drug-resistant (XDR) and pre-XDR tuberculosis: Systematic review and meta-analysis.
PLOS Glob Public Health
January 2025
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Extensively drug-resistant (XDR) and pre-XDR- tuberculosis (TB) account for approximately a third of pediatric MDR-TB cases globally. Clinical management is challenging; recommendations are based on limited evidence. We assessed the clinical outcomes for children and adolescents treated for XDR-and pre-XDR-TB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!